Veytics Intelligence
2026-10-31 · NASDAQ

Is AbbVie a Buy After Its Latest Earnings Report?

Key PointsAdjusted EPS nearly doubled, but most of that comes from last year’s big research-deal charge, and underlying growth was closer to 17%.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.